Nantes, France, November 22, 2022 – AbolerIS Pharma is a pre-clinical stage biotech company specialized in the development of innovative immunomodulators for the treatment of transplant rejection, graft-versus-host-disease and auto-immune diseases.
The company announces that it has been rewarded as one of the laureates at the REACT-EU program (acronym for “Recovery Assistance for Cohesion and the Territories of Europe”). REACT-EU is a European initiative integrated into the “Next Generation EU” recovery plan aiming at promoting the repair of damage following the crisis caused by the coronavirus pandemic COVID-19 and preparing for a green, digital and resilient recovery of the economy. REACT-EU is deployed in each French region through an addition to the 2014-2020 ERDF-ESF regional programs. Among the actions supported by REACT-EU in Pays de la Loire is support for innovative companies with high potential for job creation in the fields of energy transition, health and digital technology.
Laureate companies receive a significant financial non-dilutive support. AbolerIS Pharma was awarded almost 1.5Mio Euro to support the CMC and preclinical program of its lead compound ABIS-45RC, an anti-CD45RC monoclonal antibody.
About AbolerIS Pharma (www.aboleris-pharma.com)
Founded in November 2019 by Dr. Carole Guillonneau (Director of Research CNRS) and Dr. Ignacio Anegon (Director of Research INSERM), researchers in Unit 1064-CRTI INSERM University of Nantes, located at the Nantes University Hospital, together with Dr. François-Xavier Hubert, MD PhD. The company onboarded experienced drug developers and is focusing on the development of an innovative strategy to regulate the immune system: an anti-CD45RC monoclonal antibody. A clinical lead antibody has been selected and the GMP production has been initiated. The team has built a very strong preclinical package and is currently preparing a CTA submission for FIH studies. In October 2020, AbolerIS Pharma raised €2.5 million seed investment from a consortium comprised of Turenne Santé/Sham Innovation Santé and Newton Biocapital and obtained an exclusive worldwide license by Ouest Valorisation, a French TTO.